Transplants no benefit in advanced follicular lymphoma
Results of a systematic review and meta-analysis of randomized control trials ranging from 1947 through 2009 showed researchers that high-dose chemotherapy followed by stem cell transplantation did not improve overall survival in patients with advanced, treatment naive follicular lymphoma compared to chemotherapy alone.
The results were published in the December issue of the Journal of the National Cancer Institute (JNCI), and the research was done by Murtadha Al Khabori of the Division of Medical Oncology and Hematology at the Princess Margaret Hospital in Toronto and his colleagues.
Stem cell transplantations are not common in follicular lymphoma, and to some degree this retrospective study may help bolster current therapies of choice, the watch-and-wait as well as maintenance rituximab.
Source: JNCI
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
